<DOC>
	<DOCNO>NCT01623024</DOCNO>
	<brief_summary>Non-alcoholic fatty liver disease ( NAFLD ) represent spectrum disorder characterize predominantly macrovesicular hepatic steatosis occur individual absence significant alcohol consumption . In context possible distinguish condition simple fatty liver , histologic find presence steatosis , state non-alcoholic steatohepatitis ( NASH ) , characterize hepatocellular injury/inflammation without fibrosis . The prevalence NAFLD around 20-30 % general population . With rapid increase risk factor metabolic syndrome , NAFLD become common cause liver disease Western country . The clinical relevance NAFLD arise fact considerable proportion subject ( 20-30 % ) develop NASH , condition progress cirrhosis 15 % patient . In addition NAFLD , particularly NASH , represent cardiovascular risk factor , independent well-known condition contribute heart vascular disease . Lifestyle modification effective medical treatment recommend NASH , currently pharmacologic therapy proven benefit patient . Several pilot study , use insulin sensitizer ( thiazolidinediones metformin ) , antioxidant , like vitamin E , provide inconclusive evidence drug may improve clinical histological feature NASH . In complex completely understood pathogenic puzzle NAFLD NASH , also vitamin D might important role . Vitamin D deficiency associate many common pathological condition frequently observe NAFLD , like cardiovascular disease , insulin resistance . A recent paper Targher colleague show low vitamin D serum level NAFLD patient , identify inverse relation vitamin D level severity liver disease . In keep data , recent experimental evidence also suggest potential ability vitamin D , interaction nuclear receptor ( vitamin D receptor - VDR ) , interfere inflammatory response , T cell function fibrogenesis . Therefore consider link vitamin D serum level , severity NAFLD , risk factor NAFLD , speculate vitamin D might represent new therapeutic target management NASH patient .</brief_summary>
	<brief_title>Effect Liver Histology Vitamin D Patients With Non-alcoholic Steatohepatitis</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Fatty Liver , Alcoholic</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>1 . Patients older 18 year 2 . Histological diagnosis possible definite NASH , accord Kleiner score , within 6 month randomization . 1 . Average alcohol consumption exceed 20 g per day woman 30 g per day men least 3 consecutive month previous 5 year , evaluate selfadministrated questionnaire , 7day recall test rand confirm family member . 2 . Other cause chronic liver disease : Wilson 's disease ( normal serum ceruloplasmin ) ; alpha1antitrypsin deficiency ( normal serum alpha1antitrypsin ) ; viral hepatitis ( antiHCV HBsAg negativity ) ; primary biliary cirrhosis ( ANA &lt; 1:160 AMA negativity ) ; autoimmune hepatitis ( ANA , SMA LKM &lt; 1:160 absence histological feature autoimmune hepatitis ) ; HIV infection ( antiHIV negativity ) ; hypo hyperthyroidism ( normal TSH ) . 3 . History plan gastrointestinal bypass additional bariatric surgery/intervention . 4 . Hepatic cirrhosis ChildPugh score B C , and/or concomitant hepatocellular carcinoma 5 . Recent significant weight loss ( &gt; 5 % TBW within previous 6 month ) 6 . Recent ( within 6 month baseline liver biopsy screen visit ) concomitant use agent know cause hepatic steatosis ( corticosteroid , amiodarone , methotrexate , tamoxifen , tetracycline , high dose estrogen ( exclusion standard HRT oral contraceptive treatment ) , valproic acid ) 7 . Recent ( within 6 month baseline liver biopsy screen visit ) change dose/regimen first treatment vitamin E , Vitamin C , betaine , sadenosyl methionine , ursodeoxycholate , sylimarin , fibrate , statin , pentoxyfilline , angiotensin II inhibitor , orlistat , sibutramine . Oral hypoglycaemic agent insulin allow , provide initiate least 6 month enrollment maintain stable dos . 8 . Ongoing recent therapy ( within 6 month baseline liver biopsy screen visit ) vitamin D medication know affect vitamin D3 metabolism , include vitamin/mineral supplement . 9 . Any additional condition might interfere optimal participation study , accord Investigators opinion . 10 . Be pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>